These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1540974)

  • 21. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes.
    Ménétrier-Caux C; Bain C; Favrot MC; Duc A; Blay JY
    Br J Cancer; 1999 Jan; 79(1):119-30. PubMed ID: 10408703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of low nuclear grading of renal carcinoma cells in the functional profile of tumor-infiltrating T cells.
    Puccetti L; Manetti R; Parronchi P; Piccinni MP; Mavilia C; Carini M; Romagnani S; Maggi E
    Int J Cancer; 2002 Apr; 98(5):674-81. PubMed ID: 11920635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
    J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunological assessment of tumour infiltrating lymphocyte subsets in renal cell carcinoma patients. An analysis of immunological reaction to immuno-competent lymphocytes by interferon-gamma].
    Ohnishi T
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):216-24. PubMed ID: 1904117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of immune changes in patients with renal cancer and melanoma treated with interferon-alpha 2b.
    Tsavaris N; Baxevanis K; Kosmidis P; Papamichael M
    Tumour Biol; 1995; 16(6):365-73. PubMed ID: 7569683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12.
    Tannenbaum CS; Wicker N; Armstrong D; Tubbs R; Finke J; Bukowski RM; Hamilton TA
    J Immunol; 1996 Jan; 156(2):693-9. PubMed ID: 8543822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
    Smyth MJ; Cretney E; Takeda K; Wiltrout RH; Sedger LM; Kayagaki N; Yagita H; Okumura K
    J Exp Med; 2001 Mar; 193(6):661-70. PubMed ID: 11257133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon.
    Perez R; Padavic K; Krigel R; Weiner L
    Cancer; 1991 May; 67(10):2512-7. PubMed ID: 1901756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients.
    Sobota V; Bubeník J; Indrová M; Vlk V; Jakoubková J
    J Immunol Methods; 1997 Apr; 203(1):1-10. PubMed ID: 9134025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy for renal cell carcinoma using IFN-gamma and OK-432: in vitro study.
    Muraki J
    Keio J Med; 1990 Mar; 39(1):21-5. PubMed ID: 2113148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
    Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
    J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased frequency of interferon-gamma- and interleukin-2-producing cells in patients with atopic diseases measured at the single cell level.
    Jung T; Lack G; Schauer U; Uberück W; Renz H; Gelfand EW; Rieger CH
    J Allergy Clin Immunol; 1995 Oct; 96(4):515-27. PubMed ID: 7560664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of p38 MAP kinase during cellular activation results in IFN-gamma-dependent augmentation of IL-12 production by human monocytes/macrophages.
    Marriott JB; Clarke IA; Dalgleish AG
    Clin Exp Immunol; 2001 Jul; 125(1):64-70. PubMed ID: 11472427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of an anti-tumor polysaccharide, schizophyllan, on interferon-gamma and interleukin 2 production by peripheral blood mononuclear cells.
    Sakagami Y; Mizoguchi Y; Shin T; Seki S; Kobayashi K; Morisawa S; Yamamoto S
    Biochem Biophys Res Commun; 1988 Sep; 155(2):650-5. PubMed ID: 2971353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells.
    Smyth GP; Stapleton PP; Barden CB; Mestre JR; Freeman TA; Duff MD; Maddali S; Yan Z; Daly JM
    Ann Surg Oncol; 2003 May; 10(4):455-62. PubMed ID: 12734096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
    Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
    Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF.
    Beniers AJ; Peelen WP; Debruyne FM; Schalken JA
    Int J Cancer; 1991 Jul; 48(5):709-16. PubMed ID: 1906431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated T lymphocytes regulate hyaluronan binding to monocyte CD44 via production of IL-2 and IFN-gamma.
    Levesque MC; Haynes BF
    J Immunol; 2001 Jan; 166(1):188-96. PubMed ID: 11123292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.